☆ 4.7 Meeting Abstract

Brigatinib (BRG) in ALK plus crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.

JOURNAL OF CLINICAL ONCOLOGY (2021)

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started